Jump to content

Template:Oral hypoglycemics and insulin analogs: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
update wikilink
Empagliflozin/linagliptin
Line 179: Line 179:
* [[Dapagliflozin/saxagliptin]]
* [[Dapagliflozin/saxagliptin]]
* [[Dapagliflozin/saxagliptin/metformin]]
* [[Dapagliflozin/saxagliptin/metformin]]
* [[Empagliflozin/linagliptin]]
* [[Empagliflozin/metformin]]
* [[Empagliflozin/metformin]]
* [[Gemigliptin/rosuvastatin]]
* [[Gemigliptin/rosuvastatin]]
* [[Glibenclamide/metformin|Glibenclamide (glyburide)/metformin]]
* [[Glibenclamide/metformin|Glibenclamide (glyburide)/metformin]]
* [[Glimepiride/rosiglitazone]]
* [[Glimepiride/rosiglitazone]]
* [[Linagliptin/empagliflozin]]
* [[Linagliptin/metformin]]
* [[Linagliptin/metformin]]
* [[Metformin/acarbose]]
* [[Metformin/acarbose]]

Revision as of 16:00, 14 August 2020

This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.

To change this template's initial visibility, the |state= parameter may be used:

  • {{Oral hypoglycemics and insulin analogs|state=collapsed}} will show the template collapsed, i.e. hidden apart from its title bar.
  • {{Oral hypoglycemics and insulin analogs|state=expanded}} will show the template expanded, i.e. fully visible.